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Summary
Biomarkers provide a powerful approach to understanding the spectrum of cardiovascular diseases. 
They have application in screening, diagnostic, prognostication, prediction of recurrences and monitor-
ing of therapy. The “omics” tool are becoming very useful in the development of new biomarkers in 
cardiovascular diseases. Among them, proteomics is especially ﬁ  tted to look for new proteins in health 
and disease and is playing a signiﬁ  cant role in the development of new diagnostic tools in cardiovas-
cular diagnosis and prognosis. This review provides an overview of progress in applying proteomics 
to atherosclerosis. First, we describe novel proteins identiﬁ  ed analysing atherosclerotic plaques directly. 
Careful analysis of proteins within the atherosclerotic vascular tissue can provide a repertoire of proteins 
involved in vascular remodelling and atherogenesis. Second, we discuss recent data concerning proteins 
secreted by atherosclerotic plaques. The deﬁ  nition of the atheroma plaque secretome resides in that 
proteins secreted by arteries can be very good candidates of novel biomarkers. Finally we describe 
proteins that have been differentially expressed (versus controls) by individual cells which constitute 
atheroma plaques (endothelial cells, vascular smooth muscle cells, macrophages and foam cells) as well 
as by circulating cells (monocytes, platelets) or novel biomarkers present in plasma.
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Introduction
Cardiovascular diseases are the leading cause of death and disability in developed countries. The diag-
nosis of most cardiovascular diseases is made on clinical grounds, but there are many ancillary techniques 
that are helpful in establishing or ruling out the suspected clinical diagnosis. Among these auxiliary 
techniques, biomarkers are getting an increasing and very important role.
Biomarkers provide a powerful approach to understanding the spectrum of cardiovascular disease. 
They have applications in several areas, such as screening, diagnosis, prognostication, prediction of 
recurrences, and monitoring of therapy. Advances in genomics, proteomics, metabolomics, and bioin-
formatics have revolutionized the search for numerous putative markers that may be informative with 
regard to the various stages of atherothrombosis.
Before they are used clinically, it is important to understand their speciﬁ  c indications, to standardized 
their analytical methods, to assess their performance characteristics and to establish the incremental 
value and cost-effectiveness of different markers for given clinical indications.
1,2 Clinical application 
further requires the demonstration, in multiple prospective cohorts, that evaluation of the biomarker 
predictive of disease and adds to traditional risk factors.
3
Biomarkers
Generally, biomarkers are considered to be plasma measurements of molecules, proteins, or enzymes 
that provide independent diagnostic or prognostic value by reﬂ  ecting an underlying disease state or 102
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condition.
3 According to the deﬁ  nition proposed 
by the Medical Subject Heading (MeSH) a biomar-
ker is a biological parameter that can be measured 
and quantiﬁ  ed which serve as indices of health and 
physiology-related assessments, such as disease 
risks, environmental exposure and its effects, dis-
ease diagnosis, etc.
2 An NIH working group stand-
ardized the deﬁ  nition of a biomarker in 2001, as 
“a characteristic that is objectively measured and 
evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.”
4
The same NIH working group deﬁ  ned several 
types of biomarkers, as type O (a marker of the 
natural history of a disease and correlates longitu-
dinally with known clinical indices; e.g. blood 
pressure in patients with systemic hypertension), 
type 1 (a marker that captures the effects of a 
therapeutic intervention in accordance with its 
mechanism of action; e.g. reduction in LDL- cho-
lesterol with statins) and type 2 or surrogate end 
point (a marker that is intended to substitute for a 
clinical end point; a surrogate end point is expected 
to predict clinical beneﬁ  t -or harm or lack of ben-
eﬁ  t or harm- on the basis of epidemiological, 
therapeutic, pathophysiological, or other scientiﬁ  c 
evidence; e.g. changes in carotid intima-media 
thickness as an index of atherosclerosis).
4
A biomarker can be measured in a biological 
sample (blood, urine, etc), may be recorded in a 
patient (electrocardiogram, etc.) or can be an imaging 
test (echocardiogram, etc,). Biomarkers can indicate 
a variety of health or disease characteristics, including 
environmental factors, genetic susceptibility, clinical 
or preclinical disease, and accordingly can be 
classiﬁ  ed as antecedent biomarkers (identifying the 
risk of developing an illness), screening biomarkers 
(screening for subclinical disease), diagnostic 
biomarkers (detecting overt disease), staging 
biomarkers (categorizing disease severity), or prog-
nostic biomarkers (predicting future disease course, 
including recurrence and response to therapy, and 
monitoring efﬁ  cacy of therapy). There is a signiﬁ  cant 
overlap between these classiﬁ  cations of biomarkers, 
since type 0, 1 or 2 biomarkers can be used as ante-
cedent, diagnostic or prognostic assessment of the 
patients depending on their clinical situation.
The ideal biomarker
Independently of its use, the clinical value of a new 
biomarker will depend on its accuracy and 
reproducibility obtained in a standard fashion. 
Furthermore, it must be acceptable to the patient, 
easy to interpret by clinicians, must have high 
sensitivity and high speciﬁ  city for the outcome it 
is expected to identify, and must be able to explain 
a reasonable proportion of the outcome independ-
ently of other established predictors. The informa-
tion obtained by biomarker levels must have the 
potential to change clinical management of the 
patient in order to be cost-effective. The desired 
characteristics of a biomarker depend on its main 
use; diagnosis, prognosis, etc. Sensitivity is more 
important for diagnosis than for prognosis, for 
example.
Deﬁ  nition of abnormal biomarkers 
values
The deﬁ  nition of the abnormal value of a biomar-
ker is a key step before its use in clinical practice. 
There are several approaches to deﬁ  ne the abnor-
mal value of a biomarker: reference limit, dis-
crimination limit or threshold deﬁ  ning risk.
2 The 
reference limits are statistically derived cut-off 
points based on the distribution of values in a 
sample of reference; a sample of at least 200 peo-
ple is needed to establish the reference range or 
the interval between the maximal and the minimum 
reference value.
5 It must be known that a certain 
amount of normal patients can have abnormal 
levels of biomarkers deﬁ  ned statistically (for exam-
ple, 5% of normal patients will be beyond the 95th 
percentile if this is the limit used). The reference 
interval can be moved up and down depending on 
the clinical signiﬁ  cance of false-positive or false-
negative results. The discrimination limit allows 
the separation of the distribution of patients with 
or without the disease evaluating the overlap exist-
ing between the two populations (with and without 
disease); the discrimination threshold can also be 
moved depending on the clinical signiﬁ  cance of 
false-positive or false-negative results.
6
And ﬁ  nally, the threshold deﬁ  ning risk identiﬁ  es 
the level at which the risk increases steeply. For 
most cardiovascular risk factors, there is a con-
tinuum between the level of the risk factor and the 
presence of disease. Desirable levels are those that 
predict the lowest rate of disease, whereas the so-
called treatment levels are the one in which current 
treatment have shown in randomized trials that can 
decrease the development of disease. While desir-
able level is an epidemiological deduction, the 103
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treatment level depends on the last tested treat-
ments and usually goes down when more effective 
treatments are developed. High blood pressure
7 
and high cholesterol
8 are two good examples of 
this distinction between optimal or desirable level 
and treatment levels.
Evaluation of a biomarker
The precise evaluation of the performance of a 
biomarker depends on its main intended use. 
Biomarkers validation studies must perform a blind 
comparison of the new biomarker with a standard 
in a sample of consecutive patients with an appropri-
ate spectrum of the disease.
9 Two samples are usu-
ally needed, the derivation or training sample where 
the biomarker is ﬁ  rstly derived, and the validation 
or test set where the generalization of the prelimi-
nary results are tested.
10 Usually, the performance 
of the biomarker is better in the ﬁ  rst than in the 
second set which could be misleading. There are 
standards for designing and reporting studies of 
biomarkers validation in diagnosis and prognosis.
The accuracy of a biomarker is evaluated by 
estimation of sensitivity, speciﬁ  city and likelihood 
ratios. The receiver operating characteristic (ROC) 
curves allow estimating the performance of a 
biomarker over a range of values. It illustrates the 
trade-off between sensitivity and speciﬁ  city when 
a biomarker is used clinically for diagnosis.
11 Like-
lihood ratios are calculated with sensitivity and 
speciﬁ  city values and give the clinician more useful 
information: the likelihood of having a positive 
result in a diseased person (positive likelihood ratio) 
or of having a negative result in a healthy person 
(negative likelihood ratio).
12 Biomarkers used to 
rule-out a dangerous disease must have a high sen-
sitivity (small numbers of false negative tests and 
very low −0,10- negative likelihood ratio) whereas 
when a biomarker is used to conﬁ  rm a uncommon 
disease in asymptomatic people a high speciﬁ  city 
is needed (small number of false positive tests and 
very high −10- positive likelihood ratio).
13
A Bayesian approach, which includes pre-test 
probability of having the disease, is very important 
when using biomarkers to establish the presence 
of a disease in a given population.
14 Furthermore, 
in order to be accepted as a routine screening test, 
a biomarker must demonstrate that a strategy of 
measuring it improves patient outcomes relative 
to a conventional strategy that does not include the 
given biomarker.
2
Biomarkers are also evaluated in terms of their 
discrimination and calibration capabilities.
15 Dis-
crimination is the ability of a biomarker to separate 
disease from health (“cases” from “controls” in a 
cross-sectional study or the development of disease 
from the absence of it in a longitudinal study). The 
c statistic or concordance index is frequently used 
for this purpose as a metric of overall performance 
of a test; it is equivalent to “the area under the 
curve” in the ROC curve and expresses the prob-
ability than in two randomly paired individuals 
(with and without disease) the biomarker can 
properly tell apart the one with disease. On the 
other hand, calibration analyses the relationship 
between the ability of a biomarker to predict risk 
with the actual risk of subgroups of patients, and 
it is particularly important when the question is the 
numeric probability of disease in a given patient. 
The Hosmer-Lemeshow goodness-of-ﬁ  t statistic, 
which divides the sample into deciles of risk and 
compares the observed with the expected number 
of events, is often used as an indicator of model 
calibration.
16 Using this methodology estimation 
of risk can be performed in individuals using score 
systems that include the biomarker, such as in the 
Framingham cardiovascular risk score.
It is important to evaluate the incremental value 
of a new biomarker demonstrating the elevated risk 
of an outcome associated with higher levels of the 
new biomarker after adjustment for other estab-
lished risk factors. Hazard ratios (relative risk 
estimates from a Cox model) are frequently used 
for this purpose, as well as a probability value test 
of the signiﬁ  cance of the biomarker in the multi-
variable models. Nevertheless, the relative added 
values of new biomarkers is best evaluated by 
estimating the increment to the c statistic compared 
with that from a model that incorporates other 
previously known predictors.
17 For example, the 
Framingham coronary heart disease score is com-
posed of several biomarkers and has a c statistic 
of 0.74–0.76, which is considered appropriated
18; 
this c statistic is not incremented adding other 
biomarkers such as C-reactive protein that have 
been shown to be associated with cardiovascular 
disease. In spite of that, some biomarkers such as 
homocysteine are useful for speciﬁ  c populations 
of patients even if they do not increment the c 
statistic in the total population.
19
In studies using genetic biomarkers there is a 
major concern about false-positive associations with 
disease (or phenotypes) resulting from numerous 104
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additional factors,
20 and a replication of results in 
multiple independent samples is essential.
21
Obviously, the analytical method must be stand-
ardized to obtain accurate results of the biomarkers. 
Good quality control within the laboratories is 
needed.
22
There are many biomarkers for cardiovascular 
disease,
23–25 with different levels of evidence in 
relationship with diagnosis, prognosis and patho-
physiologic development of the disease.
2,3,26 Jaffe 
et al. have analysed the current situation of biomar-
kers for acute cardiac disease and have concluded 
that there are established biomarkers (troponins), 
potentially outdated markers (CK-MB, myoglobin 
and CK isoforms), emerging markers (C-reactive 
protein, B-type natriuretic peptide) and developing 
markers (sCD40 ligand, myeloperoxidase, 
ischemia-modiﬁ  ed albumin, pregnancy-associated 
plasma protein-A, choline, placental growth factor, 
cystatin C and fatty acid binding protein). Some 
emerging and developing markers will help provide 
a better framework for treatment of cardiovascular 
diseases in the future.
Discovery of new biomarkers
The discovery of new biomarkers is a very chal-
lenging process especially in cardiovascular dis-
ease where many genes and pathophysiologic 
pathways are involved. Two potential complemen-
tary approaches can be applied: deductive or induc-
tive strategies. In the deductive method (knowledge 
based) a direct understanding of the biological 
processes underlying atherosclerosis is needed to 
search for new molecules that can be used as mark-
ers, whereas in the inductive method (unbiased 
approach) the study of many molecules with the 
use of current techniques to characterize the bio-
molecular proﬁ  le of a stage of the disease. The 
“omics” tools are becoming very useful in the 
development of new biomarkers in cardiovascular 
disease. Among them, proteomic is especially ﬁ  t-
ted to look for new proteins in health and disease 
and is playing a signiﬁ  cant role in the development 
of new diagnostic tools in cardiovascular diagno-
sis and prognosis.
27
Proteomic Approach for the Study 
of Cardiovascular Diseases
Proteomics is the large study of the structure and 
function of proteins; it includes the rapidly evolving 
ﬁ  eld of clinical proteomics, which aims to identify 
proteins involved in human disease and understand 
how their expression, structure and function cause 
illness. Proteomics-based screening test would 
compare the proteins expressed in blood or a tissue 
sample or cells with protein patterns from patients 
known to have a particular disease. This technology 
has identiﬁ  ed proteins that offer promise as diag-
nostic or prognostic markers, or as therapeutic 
targets in a range of illness, including vascular 
diseases.
Proteomics in the ﬁ  eld 
of atherosclerosis
The mechanism by which atherosclerosis develops 
is still unclear, but some clear factors related to 
this development are hypercholesterolemia and 
accumulation of inﬂ  ammatory cells in the vascular 
wall. The ﬁ  rst signal is the formation of fatty 
streaks under the endothelium of arteries. The 
recruitment of monocytes to the lesion leads to an 
inﬂ  ammatory response and cytokine secretion. 
This fact induces the proliferation of vascular 
smooth muscle cells (VSMC) from the media and 
subsequent neointima formation. At the same time, 
necrosis of VSMCs and macrophages contributes 
to the formation of a ﬁ  brous cap that covers a lipid-
rich core. This cap keeps stable until the expression 
of proteases promotes the degradation of extracel-
lular matrix and rupture of the plaque, inducing 
thrombus formation.
28–30 Several recent reviews 
on vascular proteomics have been reported.
31–34
Until recently, the usual approach has been to 
study the role of a candidate protein supposedly 
involved in the formation or progression of the 
atherosclerotic lesion. However, with the appear-
ance of new proteomic techniques of protein 
separation (2-DE, MudPIT), and their identiﬁ  cation 
by mass spectrometry (MS), the evaluation of 
thousands of proteins at once is now possible. At 
present, it is possible to perform a differential 
proteomic approach on a variety of biological 
samples, including cells, tissues or biological ﬂ  u-
ids. In the context of biomarker discovery, bio-
logical ﬂ  uids such as plasma or urine, represent 
the most logical compartment for investigation 
because of their easy access. However, the analy-
sis of plasma is challenging because it contains a 
plethora of proteins resulting from a transient 
complex metabolic state of the whole body.
35 
Atherosclerosis is characterized by focal plaques 
from which proteins can diffuse in limited amounts 105
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into plasma where their detection and subsequent 
identiﬁ  cation is difﬁ  cult as they are masked by the 
large quantities of major plasma proteins such as 
albumin or immunoglobulins. Recent technologi-
cal improvements in depletion of abundant plasma 
proteins compatible with proteomic analysis should 
facilitate discovery of biomarkers of vascular ori-
gin, directly related to the pathology.
36,37 Another 
approach consists of the analysis of either vascular 
cells under pathological conditions or atheroscle-
rotic plaques, as compared to healthy cells or tis-
sues. A choice must be made either to study 
cellular/tissue proteins or secreted/released pro-
teins, the latter being more likely to be found in 
plasma.
Proteomic analysis of the atheroma 
plaque
The study of human atherosclerotic lesions (usually 
carotid or coronary artery segments bearing ath-
eroma plaques) is complicated owing to their cel-
lular heterogeneity (endothelial cells, VSMC, 
macrophages and foam cells, leukocyte, erythro-
cytes, platelets) and the different degree of devel-
opment and complication. Proteins are the major 
mediators of most pathological processes and are 
the most suitable molecules for use as biomarker 
and risk factors, as well as targets for disease treat-
ment. Thus, to have a better understanding of 
atherosclerosis progression it is necessary to iden-
tify and characterize the expressed proteins in the 
arterial wall and in the atheroma plaques. Most 
likely, the proteins expressed (and/or secreted) for 
the multiple cell types present in the atherosclerotic 
plaque, can potentially contribute to the pathogen-
esis of atherosclerosis. In fact many proteins 
(growth factors, lipid associated proteins, mem-
brane receptors, tissue enzymes, etc.) have all been 
implicated in the complex process of atherogen-
esis. Thus, proﬁ  ling of protein expression from 
atherosclerotic tissue samples can provide a 
molecular snapshot of the functional and patho-
logical state of the plaques. With these goals in 
mind several experimental approaches can be 
applied: 1) to determine all the expressed proteins 
solubilizing the tissue and analyzing the proteins 
by 2-DE or MudPIT.
38–40 2) to focus in a selected 
group of proteins using antibody arrays or even 
restrict the analysis to a very speciﬁ  c set such as 
those involved in signaling pathways using 
reverse phase arrays and specific antibodies 
(phosphoproteome).
41 3) to study the proteome of 
arteries and atherosclerotic plaques using direct 
tissue proteomics (DTP), a new methodology 
which allows the identiﬁ  cation of proteins directly 
in formalin ﬁ  xed parafﬁ  n-embebed tissue sam-
ples.
42 4) by MS-Imaging, a suitable method to 
obtain protein and peptide proﬁ  les and images 
(two-dimensional protein maps) from thin frozen 
tissue sections.
43 5) to focus on particular subpro-
teomes (intima, extracellular proteins and proteo-
glycans, neovascularization associated proteins, 
etc.)
44 and 6) to asses the proteins expressed in 
relatively pure cell populations, obtained from the 
atherosclerotic sample tissues, using laser micro-
dissection.
45 Several examples of these approaches 
are described below:
1)When 2-DE proﬁ  les of human stable lesions 
plaques where compared with plaques containing 
a thrombus
38 these showed 71 spots exclusive from 
stable plaques and 29 exclusive from plaques con-
taining a thrombus. The most interesting ﬁ  nding 
is the difference found in the expression of α1-
antitrypsin (ATT) between the stable plaque and 
the one containing a thrombus. The stable plaque 
showed the expression of 6 isoforms of ATT versus 
only one isoform present in the thrombotic plaque, 
so the up regulation of ATT could be considered 
as a protective strategy against atherosclerosis. 
Using an apoliprotein-E (apo-E) deﬁ  cient mice 
model, the protein changes analyzed during various 
stages of atherogenesis were studied by 2DE and 
MS.
39 An average of 1500 spots were visualized 
in the 2DE aorta sample from which 79 protein 
were found to be altered during the different stages 
of atherogenesis.
39 Likewise in a rat model of 
coronary atherosclerosis induced by a high cho-
lesterol diet, 46 proteins were differentially 
expressed in the aortic tissue of atherosclerotic rats 
in comparison with aortas from control animals. 
Among the upregulated proteins were redox 
enzymes and those with decreased levels included 
HSP-27, calcium calmodulin kinase II inhibitory 
protein and fructose biphosphate aldolase.
40
2) Using antibody arrays, Slevin et al.
41 have 
identiﬁ  ed novel proteins associated with the develop-
ment of unstable human carotid plaques. They com-
pared protein expression in carotid endarterectomy 
samples histologically deﬁ  ned as stable and unstable. 
Their results could indicated that the modulation of 
these novel cell signaling proteins can be useful in 
therapy of angiogenesis and apoptosis, designed to 
reduced unstable plaque formation.
41106
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3) using DTP in 35 human coronary 
atherosclerotic samples more than 800 proteins 
were identiﬁ  ed, including extracellular matrix 
proteins, lipid binding and metabolism associated 
proteins, inﬂ  ammation related proteins and apop-
totic-cell phagocytic ligands and receptors. The 
presence of these proteins in the tissue was con-
ﬁ  rmed by immunohistochemistry.
42
4) MS-imaging of tissues is a powerful tool for 
visualizing the spatial distribution of proteins on 
the surface of the tissue and it has been applied in 
several pathologies.
43 However it has not been 
applied yet on atherosclerotic or normal arteries 
for a number of reasons. In contrast, the application 
of TOF-SIMS in the vascular pathology area has 
permitted to generate, for the ﬁ  rst time, molecular-
ions images of human atherosclerotic plaques and 
rat aortic walls.
46,47 In TOF-SIMS imaging detailed 
chemical information of the upper most molecular 
layers of a solid surface can be obtained at a sub-
micrometer lateral resolution.
48 All the molecules 
with mw 1500 Da can be, in principle, detected. 
Surface rastering from atherosclerotic lesion thin-
sections generated numerous secondary ion signals 
including nonesteriﬁ  ed fatty acids, cholesterol, 
vitamin E, phosphatidic acids, phosphatidylinosi-
tols and triglycerides. Speciﬁ  c patterns for most of 
these compounds could be observed on apparently 
homogeneous tissue as it is the vascular muscle 
cell of the intima.
46
5) In humans proteoglycans of intimal hyper-
plasia are believed to play an important role in the 
development of atherosclerosis. A comparison 
between atherosclerotic-prone internal carotid 
artery and the atherosclerotic-resistant internal 
thoracic artery showed an enhanced deposition of 
lumican in atherosclerotic-prone arteries.
44 This 
signiﬁ  cant difference is present before the ath-
erome plaque formation, but the factors respon-
sible for this difference are unknown. Another 
proteomic approach that analyzed a particular 
subproteome was performed by Martinet et al.
49,50  
by Western array using 823 monoclonal antibodies. 
They compared human atherosclerotic carotid 
arteries versus healthy mammary arteries and 
reported seven proteins with enhanced expression 
levels of 5-fold relative difference. One of them, 
ALG-2 is a positive mediator of apoptosis, phe-
nomenon that is believed to be implicated with 
plaque instability. The diminished levels observed 
for ALG-2 suggest a survival mechanism of the 
atherosclerotic plaque.
6) The isolation of macrophage foam cells from 
arterial lesions has been applied to study the gene 
expression of these cells.
45 This method is now 
been used for proteomic analysis of foam and 
endothelial cells from atherosclerotic lesions (De 
la Cuesta et al. unpublished results).
Proteomic analysis of the secretome 
of atheroma plaque
An alternative strategy to the study of the tissue is 
to examine the proteins secreted by atherosclerotic 
plaques. The interest of the deﬁ  nition of the ath-
eroma plaque secretome resides in that proteins 
secreted or released by the artery wall or the cells 
within the tissue, constitute the best candidates for 
potential novel biomarkers that could be detected 
subsequently in blood or plasma. In order to easily 
identify those proteins which are secreted or 
released by atherosclerotic plaques in extracellular 
compartments, we have described
51–53 a novel 
approach by which secretomes from normal and 
atherosclerotic arteries can be obtained incubating 
endarterectomy samples in a protein-free culture 
medium and analyzing the proteins secreted into 
the medium. By focusing on only the secreted 
proteins found in the cell culture media, there 
would be an intended bias toward those proteins 
that would have a higher probability of later being 
found in plasma. We have shown that, in human 
carotid atherosclerotic plaques the more complex 
the lesion, the higher the number of proteins 
secreted by the plaque.
51 Among the differentially 
secreted proteins decreased levels of phosphory-
lated HSP-27 were found in the culture medium 
of atherosclerotic plaques in comparison with 
healthy mammary arteries. These data were sup-
ported by the ﬁ  nding that HSP-27 plasma levels 
were diminished in patients with carotid athero-
sclerosis compared to normal controls indicating 
that this protein could be a novel biomarker of 
atherosclerosis in relation with healthy subjects.
54 
The pathological signiﬁ  cance of decreased HSP-27 
plasma levels is unknown but it is conceivable that 
the decreased HSP-27 released by atherosclerotic 
plaques could be caused by proteolysis of the pro-
tein in the tissue owing to the action of the proteases 
present in the plaques.
55 A potential drawback in 
the study of secretomes using cultures of artery 
segments is that many of the proteins identiﬁ  ed in 
the culture supernatants can be of plasma origin 
(contaminants). Thus, to validate this approach it 107
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is essential to identify the true secretome, in other 
words, the identiﬁ  cation of proteins which are 
actively synthesized and secreted by the normal 
and pathological arterial wall. Very recently we 
have studied the effect of atorvastatine alone or 
combined with amlodipine in the protein secretion 
profile of atherosclerotic plaques.
52 It is well 
known that a combined treatment produces a higher 
reduction in the incidence of cardiovascular events 
than each drug administered alone. The addition 
of both drugs to complicated atherosclerotic seg-
ments normalized the levels of the majority of the 
released proteins. Thus, the application of this 
proteomic strategy has permitted the identiﬁ  cation 
of novel therapeutic targets by which these drugs 
could promote their additive effects.
52
All the cell types that make up the atheroma 
plaque are able to secrete proteins, thus contribut-
ing to the composition of the secretome. For 
example, in the secretome of VSMCs in culture,
56,57 
18 different proteins have been identiﬁ  ed, with a 
wide range of biological functions. Similarly, the 
secretome of human macrophages has been 
recently reported.
58
Proteomic analysis of individual 
constituents of atheroma plaque
An alternative to studying blood vessel is to use 
cultured cells under conditions mimicking the 
situation in atherosclerotic lesions. This is an 
advantageous system that permit the selection of 
cell type, treatment with different agents, stimu-
lants and drugs and to determine the effects on the 
expressed proteins.
Endothelial cells (EC)
The formation, development, progression and com-
plication of atherome lesions are closely related to 
endothelial dysfunction. Hence the study of EC is of 
prime importance. Endothelial cells can be harvested 
from a variety of vessels but most of our knowledge 
in vascular pathology come from HUVECS (human 
umbilical vein endothelial cells).
59 The initial studies 
described the protein expression map of primary 
cultures of HUVECS and several proteins were 
identiﬁ  ed implicated in apoptosis, senescence and 
coagulation, including cathepsin B, a protease 
upregulated in atherosclerotic lesions with senes-
cence-associated phenotypes.
60 The effect of oxLDL 
on EC function is one of the earliest events in the 
pathogenesis of atherosclerosis. The effect of oxLDL 
on EC was studied by Kinumi et al. (2005)
61 that 
found three proteins, nucleohosmin, stathamin and 
nucleolin, that were differentially expressed and 
phosphorylated. It was suggested that the process of 
phosphorylation/dephosphorylation of these proteins 
contributed to the suppression of EC proliferation. 
The effect of genistein (a component of soy) on the 
expression of proteins in EC exposed to oxLDL 
reversed 27 out of 47 proteins altered by oxLDL. 
These data help to explain some of the proathero-
genic properties of oxLDL and the capacity of 
genistein to protect from these effects.
62 Using 
bovine aortic endothelial cells, a signiﬁ  cant number 
of proteins were identiﬁ  ed with altered levels in 
response to shear stress, a well known factor con-
tributing to atherogenesis. Some of these proteins 
are involved in signaling pathways including integ-
rins and G-protein coupled receptors.
63 The caveolae 
and lipid rafts associated proteins of EC have been 
described recently and could serve as the basis for 
future studies considering the key role of these mem-
brane microdomains in signal transduction, cellular 
transport and cholesterol homeostasis.
64,65
Two annotated 2-DE protein maps of EC are 
available on the web at (http://www.huvec.com; 
http://www.pharma.ethz.ch/bmm/div/HUVEC/
HUVEC/.)
Vascular smooth muscle cells (VSMC)
Cellular proliferation and migration of VSMC are 
considered to be key events in the pathogenesis of 
atherosclerosis. This is feasible because VSMC are 
cells capable to switch between a contractile and 
an activated phenotype under the effect of soluble 
serum factors.
66 As a consequence of endothelial 
dysfunction vascular permeability increases and 
many serum components come into direct contact 
with VSMC inducing the change from a resting 
VSMC to an activated-proliferating phenotype. To 
identify changes in speciﬁ  c proteins associated 
with both cellular phenotypes, a comparative 2-DE 
analysis was performed on protein extracts from 
quiescent rat aorta VSMC and VSCM exposed to 
growth factors. More than 100 proteins were 
upregulated and 154 downregulated in activated 
cells compared with the quiescent ones.
67 Like-
wise, proteins associated with either hyperplastic 
or hyperthrophic growth due to the exposure of 
VSMC to growth factor were determined. Among 
the upregulated proteins there were chaperones, 108
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factors involved in protein synthesis and cytoskeletal 
proteins such as vimentin and actin.
68 The effect 
in the protein expression levels induced by treat-
ment of human aortic VSMC with oxLDL versus 
nLDL was studied using antibody arrays. Among 
the upregulated proteins were adhesion molecules, 
signal transduction proteins and proteins involved 
in lipoprotein metabolism.
69 Underexpressed pro-
teins included cytoskeleton proteins and growth 
factors. Lee et al. (2006)
70 studied alteration in 
protein expression in VSMC under oxidative stress 
(exposing the cells to H2O2), a phenomenon that 
plays a key role in the pathophysiology of vascular 
diseases. The most relevant VSMC proteins altered 
were those related to antioxidant, cytoskeleton and 
muscle contraction.
70
As mechanical forces play an important role in 
the pathogenesis of atherosclerosis the expression 
changes in the protein proﬁ  le due to hemody-
namical stress were also studied in VSMCs. This 
study showed that three proteins, gelsolin, HSP-27 
and CapZ had their levels altered.
71
Macrophages and foam cells
Inﬂ  ammation plays a central role throughout the 
entire atherosclerotic process and monocytes/mac-
rophages (and inﬁ  ltrating T lymphocytes) are the 
main cells involved in this inﬂ  ammatory reaction. 
Different studies have reported the proteome of 
monocytes in basal and under proinﬂ  ammatory 
conditions.
72–75 In atherosclerotic lesions mono-
cytes migrate into the vessel wall and differentiate 
into macrophages which become lipid-loaded after 
uptake of oxLDL. Thus, several studies examined 
the effect of oxLDL on the protein expression 
levels of macrophages.
76–79 Collectively it was 
shown that more than 100 proteins were altered as 
consequence of the oxLDL treatment and they can 
be grouped in metabolic proteins, components of 
differentiation pathways and antioxidant proteins. 
A group of antioxidant enzymes were also over-
expressed by mature dendritic cells which are 
present in advanced atherosclerotic plaques. The 
potential role as biomarkers of these proteins 
expressed by macrophages is at present 
unknown.
Circulating cells
The proteome of the majority of circulating cells 
has recently been described including erythro-
cytes, neutrophils, lymphocytes, monocytes and 
platelets.
31,32 Herein only monocytes and platelets 
will be discussed as they are providing new 
proteins that could potentially be considered as 
biomarkers.
Monocytes
To search for novel biomarkers in circulating 
monocytes, using proteomic approaches can be a 
fruitful strategy considering that monocytes are 
easily accessible and essential cells that participate 
throughout the atherosclerotic process. However 
it is important to be aware of two aspects: ﬁ  rst is 
the heterogeneity of human monocytes as deter-
mined by the expression of surface markers (CD14, 
CD16, MHC class II, CD32, CCR5/CCR2) that 
allows to classify monocytes in several subsets 
which reﬂ  ect development stages and specializa-
tion within their environments.
80 In addition it is 
essential to consider the proteome variance in the 
control population when performing protein proﬁ  l-
ing comparisons of monocytes derived from dis-
ease versus control populations.
81 The role of 
monocytes in the progression of the atheroma 
plaque has been described above. It has been 
recently shown that a population of monocytes/
macrophages emigrate from atherosclerotic lesions 
and re-entry into the blood. Thus, monocytes may 
serve as reporters, providing information reﬂ  ecting 
directly the state of the atherosclerotic process.
82 
A good method to retrieve this information from 
monocytes is to analyze their expressed proteins. 
Hence we have examined whether circulating 
monocytes from acute coronary syndrome (ACS) 
patients express speciﬁ  c proteins that could serve 
as individual markers or deﬁ  ne a characteristic 
proﬁ  le. It was shown that 21 proteins were dif-
ferentially expressed by monocytes from ACS 
patients in comparison with healthy subjects.
83 The 
number of proteins with altered expression in ACS 
was maximal on admission, and decreased progres-
sively, until the expression of only ﬁ  ve proteins 
was abnormal at six months. These ﬁ  ve proteins 
were identically altered in stable patients. Thus, 
six months after an ACS, the acute changes in 
monocyte protein expression disappear, showing 
a pattern similar to that of stable CAD. Among the 
identiﬁ  ed proteins, a 32 kDa protein corresponding 
to the mature form of Cathepsin D was shown to 
be upregulated in monocytes of ACS patients. 
Interestingly, treatment with atorvastatin could 
modulate some of the altered proteins in the 109
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monocytes from ACS patients. Treatment with 
atorvastatin favored the reversion to normal levels 
in 8 protein, 2 proteins were partially normalized, 
and 11 proteins appeared for the ﬁ  rst time as con-
sequence of the statin treatment.
84
Platelets
Platelets play a critical role in hemostasis of the 
vessel wall: when the endothelium is damaged, 
activated platelets adhere to the ECM components 
contributing to the healing process. The proteome 
of platelets in a basal state has been extensively 
studied and numerous proteins involved in essen-
tial cellular functions, such as signal transduction, 
modulation of the cytoskeleton and apoptosis have 
been identiﬁ  ed.
85–90 However the proteome of 
platelets is particularly dynamic, depending of their 
state of activation. Thus, the study of activated 
platelets is very important in relation with the 
atherosclerotic process since activated platelets 
adhere to atherosclerotic lesions and could be a 
source of plaque biomarker as they release proteins 
after activation. In thrombin activated platelets 
more than 300 proteins have been identiﬁ  ed in 
several studies.
91–97 Some of the identiﬁ  ed proteins 
were not previously attributed to platelets (secre-
togranin, cycloﬁ  lin A, calumenin), were not pres-
ent in normal arteries but were clearly identiﬁ  ed 
in human atherosclerotic lesions. Thus, these pro-
teins are very promising candidates as novel bio-
markers.
Plasma
Human plasma is a rich source of proteins and other 
metabolites which reﬂ  ect the physiological or 
clinical status of patients. The protein concentra-
tion in plasma is tightly controlled, thus variations 
in concentration can be considered as an indicator 
of the current state of health.
98 Hence plasma is a 
primary clinical specimen with 20 major proteins 
comprising 99% of the plasma proteome and the 
rest of the proteins making up 1% of the plasma 
content. The challenge is thus to reach this 1% 
where it is supposed some novel biomarkers can 
be potentially found.
99 For this purpose it is essen-
tial to deplete plasma of the most abundant pro-
teins.
100,101 To identify low-abundance proteins, 
plasma samples from 53 patients (a total volume 
of 6 liters) with coronary artery disease (CAD) and 
53 control subjects (6 liters of plasma) were pooled 
and analyzed by LC-MS/MS, after removal of 
albumin and immunoglobulins and enrichment in 
smaller proteins (20–40 kDa). Of the 731 pro-
teins identiﬁ  ed, 95 were differentially expressed 
in CAD patients and could be candidates for vali-
dation studies in larger clinical studies.
102 Very 
recently it has been shown that proteins derived 
from tissues can be detected in plasma directly by 
MS analysis, providing a conceptual basis for 
plasma protein biomarker discovery and analy-
sis.
103 One of the major clinical complications of 
atherosclerosis is the impairment of blood ﬂ  ow to 
the lower extremity which is commonly referred 
to as peripheral artery disease (PAD). For a number 
of reasons PAD is underdiagnosed
104 despite this 
disorder affects more than 10 million individual in 
USA and is also prevalent in Europe and Asia. Very 
recently Wilson et al.
105 have studied the proteomic 
proﬁ  le of 371 subjects in three sequential groups 
(discovery, initial validation and validation) and 
found that plasma levels of β2-microglobulin are 
elevated in patients with PAD and that β2-micro-
globulin levels independently correlate with the 
severity of the disease. These are very promising 
data although some potential limitations have been 
discussed.
104 Similarly, the MALDI-TOF spectra 
of peptides from the sera of normal and patients 
with myocardial infarction (MI) produced patterns 
that could help in the diagnosis of MI.
106 Kierman 
et al.
107 have used a multiplexed MS immunoassay 
(MSIA) for the detection of MI and two novel 
biomarkers, serum amyloid A1α and S-sulfated 
transthyretin, were found to be present in the sera 
of these patients. Both proteins were subsequently 
validated in a large cohort of patients. In mice it 
has been tested whether protein microarray based 
measurements of circulating proteins can predict 
the severity of atherosclerotic disease. From a total 
of thirty inﬂ  ammatory markers a subset of proteins 
were identify that classify and predict severity of 
atherosclerotic disease.
108
Lipoproteins are shuttling hydrophobic mic-
roparticles, formed for lipids and proteins, that 
travel from sites of absorption and production to 
sites of storage and excretion trough the blood 
system. Lipoproteins are involved in atherogenesis 
but the molecular mechanisms by which participate 
in the genesis and progression of atherosclerotic 
plaques are not fully elucidated. In recent years 
different proteomic approaches have been used to 
analyze the protein composition of HDL, LDL and 
VLDL and numerous novel proteins (and isoforms) 
have been identified in the three types of 110
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lipoproteins.
109–115 Thus further research is needed 
to establish their putative role in atherosclerosis 
and their potential usefulness as biomarkers.
The HUPO Plasma Proteome consortium has 
identiﬁ  ed a group of 345 cardiovascular-related 
proteins that could constitute a baseline proteomic 
blueprint for the future development of biosigna-
tures for cardiovascular diseases.
116 These proteins 
can be organized in eight groups: markers of 
inﬂ  ammation, and/or cardiovascular disease, vas-
cular and coagulation, signaling, growth and dif-
ferentiation, cytoskeletal, transcription factors, 
channel/receptors and heart failure and remodeling. 
Likewise, Anderson, L. (2005) has compiled a list 
of 177 candidate biomarker proteins with reported 
associations to cardiovascular disease and stroke.
117 
It is reasonable to consider that all these proteins 
may serve as the basis for further research. How-
ever this approach is inherently limiting and fails 
to allow for discovery of totally novel proteins 
involved in cardiovascular diseases. It is more 
challenging to use unbiased proteomic approaches 
to identify undiscovered novel proteins that can be 
true biomarkers and potential targets for the treat-
ment of these pathologies.
Urine
Urinary proteomics is emerging as a powerful non-
invasive tool for diagnosis and monitoring a vari-
ety of human diseases. Urine presents a rich source 
of information related to function of many integral 
organs.
118 Changes in the pattern of urinary protein 
excretion are not necessarily restricted to nephrou-
rological diseases. Thus, microalbuminuria is a 
clinically important marker not only of early dia-
betic nephropathy but also of concomitant cardio-
vascular disease. In this sense, Zimmerli et al.
119 
have tested whether signature of urinary polypep-
tides can contribute to the existing biomarkers for 
coronary artery disease (CAD). They examined a 
total of 359 urine samples from 87 patients with 
severe CAD and 283 controls using capillary elec-
trophoresis on line to ESI-TOF-MS, characterizing 
more than 100 polypeptides. They found a panel 
of 15 polypeptides which distinguished between 
presence and absence of disease and identiﬁ  ed ﬁ  ve 
of them which corresponded to collagen type I or 
type III fragments. These collagens are predomi-
nant proteins in the arterial walls and are present 
in the thickened intimae of atherosclerotic 
lesions.
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